Cellcept

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis9
13Multiple sclerosis/Neuromyelitis optica4
42Polyarteritis nodosa5
IDDisease name (Link within this page)Number of trials
43Microscopic polyangiitis3
49Systemic lupus erythematosus6

11. Myasthenia gravis


Clinical trials : 439 / Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

42. Polyarteritis nodosa


Clinical trials : 15 / Drugs : 22 - (DrugBank : 16) / Drug target genes : 26 - Drug target pathways : 104 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

43. Microscopic polyangiitis


Clinical trials : 95 / Drugs : 65 - (DrugBank : 23) / Drug target genes : 14 - Drug target pathways : 87 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,227 / Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries